<DOC>
	<DOCNO>NCT00066885</DOCNO>
	<brief_summary>This Phase 1/2 clinical trial multi-center , open-label study three main objective . The first ( Phase 1A ) determine maximum-tolerated dose DN-101 administer combination Taxotere ( docetaxel ) every three week ( close ) . The second determine maximum-tolerated dose DN-101 administer weekly combination Taxotere ( docetaxel ) devery three week ( open ) . The third evaluate safety objective tumor response rate combination NSCLC . DN-101 dos escalate three dosing level . Patients receive oral DN-101 day one , follow intravenous docetaxel day two 21-day cycle . Treatment cycle repeat dose level 21 day disease progression unacceptable toxicity .</brief_summary>
	<brief_title>Study DN101 Taxotere Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>DN-101 oral anti-cancer therapy solid tumor various hematologic malignancy . DN-101 unique formulation calcitriol specifically design use cancer . Calcitriol naturally occur hormone potent biologically active form vitamin D. In high dos , calcitriol active many laboratory animal model cancer synergistic many commonly use chemotherapeutic agent . Until recently , clinical use calcitriol anti-cancer therapy limit hypercalcemia dos require anti-tumor activity . Based upon clinical result date , Novacea believe successfully develop solution problem development DN-101 . Chemotherapy NSCLC , curative , show prolong survival patient unresectable disease . A number different chemotherapy agent show single-agent activity NSCLC . These include cisplatin , carboplatin , vinorelbine , gemcitabine , paclitaxel docetaxel . For first-line therapy Stage IIIB Stage IV NSCLC , agent generally use combination . In case , first-line chemotherapy consist platinum-based agent , either cisplatin carboplatin , another chemotherapeutic . Only one agent , TaxotereÂ® , approve United States Food Drug Administration use second-line chemotherapy NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histopathologically cytologically proven nonsmall cell carcinoma lung ( NSCLC ) , either Stage IIIB Stage IV , progress first secondline chemotherapy Measurable disease RECIST criterion Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 1 Life expectancy &gt; 3 month Age &gt; 18 year Agrees use adequate contraception throughout treatment period least 6 month follow treatment Able give inform patient consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>DN101</keyword>
	<keyword>Calcitriol</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Taxotere</keyword>
</DOC>